ImmuCell Corporation — FY2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012. The filing also reports unaudited fourth-quarter results. ImmuCell develops and sells animal-health products for the dairy and beef industries. First Defense, a calf-scours preventive, generated 89% of FY2012 product sales; Mast Out, a treatment for subclinical mastitis, remained in development and was not approved for sale.
Financial performance and position
| Metric | FY2012 | FY2011 |
|---|---|---|
| Product sales | $5.390 million | $5.111 million |
| Gross margin | $3.054 million (57% of sales) | $2.814 million (55%) |
| Operating income (loss) | $245,000 | ($633,000) |
| Net income (loss) | $90,000; $0.03 per diluted share | ($410,000); ($0.14) per share |
| Cash from operating activities | $344,000 | ($37,000) |
| Cash, equivalents and short-term investments at year-end | $4.914 million | $4.960 million |
| Net working capital at year-end | $6.697 million | $6.516 million |
| Bank debt at year-end | $1.268 million | $1.441 million |
- Sales rose 5.5% year over year. First Defense sales increased 5%; international sales increased 13% overall. Wipe Out Dairy Wipes sales fell 6%, and California Mastitis Test sales fell 28%.
- Product development expense fell 47% to $918,000, principally because major Mast Out clinical studies were largely complete. Sales and marketing expense rose 12% to $973,000; administrative expense rose 7% to $918,000.
- Fourth-quarter 2012 sales were $1.421 million, gross margin was $750,000, operating income was $12,000, and net loss was $17,000.
- Capital investments were $275,000 in 2012. The company repaid $173,000 of bank debt. It reported a $500,000 revolving credit line available as needed and a covenant requiring at least $1 million in unrestricted cash, equivalents and short-term investments.
Material changes, outlook and key developments
- The return to annual profitability followed four consecutive years of losses in 2008–2011. Management attributed the 2012 improvement principally to lower product-development spending and higher First Defense sales.
- Management expected 2013 results to be near breakeven, with product-development expenses rising from 2012 levels but remaining below 2011 levels. It budgeted sales and marketing spending of up to 20% of product sales.
- Mast Out’s FDA review had received complete letters for environmental impact, target animal safety and effectiveness. The human-food-safety analytical method was submitted in Q4 2012; management expected the section-complete letter in the second half of 2013. The chemistry, manufacturing and controls submission was withdrawn in Q4 2012 following changes in regulatory and manufacturing strategy and was to be revised.
- Management estimated that leasing and modifying an existing facility for Mast Out active pharmaceutical ingredient production could require $11–$13 million; a new facility was estimated at about $13 million. The company had not begun construction or leasing and was seeking debt, equity, partner investment and possible incentives. Funding and FDA approval were not assured.
- The AgriLabs sales and marketing collaboration for First Defense ended December 31, 2012 and was not extended. In Q1 2013, the company made its first significant sale of Nisin-based pet wipes to Bayer Animal Health.
Risks, contingencies and other notable items
- ImmuCell depends heavily on First Defense sales to support operations. Two distributors accounted for 49% of product sales in 2012, and 42% of trade receivables were due from them.
- Mast Out commercialization depends on substantial additional financing, manufacturing scale-up, completion of FDA review and eventual product-market acceptance. The company also identified potential risks involving third-party manufacturers, cultured dairy-product processing, and the uncertain size and economics of the target market.
- Customer demand is exposed to dairy and beef industry conditions. Management cited high feed costs and a 2012 milk-to-feed ratio of 1.52, the lowest since the measure began in 1985.
- Other risks include competition from larger animal-health companies, biological variability and raw-material supply, regulatory compliance, key-person dependence, and foreign-exchange effects. The filing notes a 2007 FDA warning letter concerning cGMP deficiencies; management stated it believed the cited deficiencies had been substantially corrected, but no further FDA communication had been received.
- No legal proceedings or off-balance-sheet arrangements were reported. No dividends had been paid, and none were expected in the foreseeable future. The independent auditor gave an unqualified opinion on the financial statements; management assessed internal control over financial reporting as effective, without an auditor attestation.
Important facts for investors to verify
- Progress, timing and remaining cost of Mast Out’s FDA review, manufacturing validation and commercial-scale production.
- Whether a financing or commercial partner is secured for the estimated $11–$13 million facility investment, and the resulting dilution, debt and control implications.
- Whether First Defense sales growth and gross margin can continue, particularly after the AgriLabs collaboration ended.
- Distributor concentration, receivables collection, bank-covenant compliance and the $1 million minimum liquidity requirement.
- Whether the company’s near-breakeven 2013 outlook is achievable as product-development spending increases.